However, a recent study in a murine breast cancer model showed that verteporfin PDT does indeed destroy lymphatic vessels—a combination treatment with anti-VEGF blockade or with lenalidomide (a lymphangiogenesis inhibitor) actually reduced tumor responsiveness to PDT and abrogated the potentiation of therapy by anti-PD1 monoclonal antibodies (mAbs); these effects were largely due to the reduced migration of DCs from the tumor to the DLNs [105]. The gene discussed is PDCD1; the disease is breast cancer.